NasdaqGS - Delayed Quote USD
Akero Therapeutics, Inc. (AKRO)
38.87
-1.09
(-2.73%)
At close: May 16 at 4:00:02 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 9 |
| Avg. Estimate | -0.82 | -0.95 | -3.77 | -4.47 |
| Low Estimate | -0.94 | -1 | -3.94 | -4.92 |
| High Estimate | -0.59 | -0.91 | -3.46 | -4.02 |
| Year Ago EPS | -0.81 | -1.05 | -3.75 | -3.77 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.89 | -0.93 | -1.12 | -0.99 |
| EPS Actual | -0.81 | -1.05 | -0.99 | -0.9 |
| Difference | 0.08 | -0.12 | 0.13 | 0.09 |
| Surprise % | 8.80% | -12.36% | 11.83% | 9.24% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.82 | -0.95 | -3.77 | -4.47 |
| 7 Days Ago | -1 | -1.03 | -4.05 | -4.53 |
| 30 Days Ago | -1 | -1.03 | -4.05 | -4.53 |
| 60 Days Ago | -1.07 | -1.1 | -4.23 | -4.66 |
| 90 Days Ago | -1.11 | -1.19 | -4.84 | -4.94 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 3 | 1 |
| Up Last 30 Days | 1 | 1 | 3 | 2 |
| Down Last 7 Days | -- | -- | 1 | 2 |
| Down Last 30 Days | -- | -- | 1 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AKRO | -1.47% | 9.58% | -0.43% | -18.63% |
| S&P 500 | 13.31% | 2.67% | 7.78% | 13.74% |
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 5/13/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/3/2025 |
| Maintains | UBS: Buy to Buy | 1/31/2025 |
| Upgrade | B of A Securities: Neutral to Buy | 1/30/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/27/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/16/2025 |
Related Tickers
ETNB 89bio, Inc.
7.78
+1.77%
CYTK Cytokinetics, Incorporated
31.00
+3.89%
MDGL Madrigal Pharmaceuticals, Inc.
290.96
-0.29%
SRRK Scholar Rock Holding Corporation
30.55
-0.91%
XENE Xenon Pharmaceuticals Inc.
30.29
+2.43%
STOK Stoke Therapeutics, Inc.
9.76
+1.35%
RYTM Rhythm Pharmaceuticals, Inc.
59.93
-0.42%
SLNO Soleno Therapeutics, Inc.
75.01
-0.08%
CRNX Crinetics Pharmaceuticals, Inc.
31.24
+0.10%
BHVN Biohaven Ltd.
16.02
+1.26%